AAPL   316.73 (-0.68%)
MSFT   181.57 (-1.06%)
FB   232.20 (-1.15%)
GOOGL   1,421.37 (+0.58%)
AMZN   2,421.86 (-0.62%)
NVDA   348.71 (-3.42%)
CGC   20.01 (+3.04%)
BABA   201.72 (+1.01%)
MU   45.80 (+1.91%)
GE   6.80 (+6.08%)
TSLA   818.87 (+0.24%)
AMD   53.19 (-3.59%)
T   30.82 (+3.15%)
ACB   15.61 (-2.50%)
F   5.84 (+3.36%)
GILD   73.18 (-0.22%)
DIS   120.95 (+2.48%)
NFLX   414.77 (-3.39%)
BAC   24.28 (+7.15%)
BA   144.73 (+5.24%)
AAPL   316.73 (-0.68%)
MSFT   181.57 (-1.06%)
FB   232.20 (-1.15%)
GOOGL   1,421.37 (+0.58%)
AMZN   2,421.86 (-0.62%)
NVDA   348.71 (-3.42%)
CGC   20.01 (+3.04%)
BABA   201.72 (+1.01%)
MU   45.80 (+1.91%)
GE   6.80 (+6.08%)
TSLA   818.87 (+0.24%)
AMD   53.19 (-3.59%)
T   30.82 (+3.15%)
ACB   15.61 (-2.50%)
F   5.84 (+3.36%)
GILD   73.18 (-0.22%)
DIS   120.95 (+2.48%)
NFLX   414.77 (-3.39%)
BAC   24.28 (+7.15%)
BA   144.73 (+5.24%)
AAPL   316.73 (-0.68%)
MSFT   181.57 (-1.06%)
FB   232.20 (-1.15%)
GOOGL   1,421.37 (+0.58%)
AMZN   2,421.86 (-0.62%)
NVDA   348.71 (-3.42%)
CGC   20.01 (+3.04%)
BABA   201.72 (+1.01%)
MU   45.80 (+1.91%)
GE   6.80 (+6.08%)
TSLA   818.87 (+0.24%)
AMD   53.19 (-3.59%)
T   30.82 (+3.15%)
ACB   15.61 (-2.50%)
F   5.84 (+3.36%)
GILD   73.18 (-0.22%)
DIS   120.95 (+2.48%)
NFLX   414.77 (-3.39%)
BAC   24.28 (+7.15%)
BA   144.73 (+5.24%)
AAPL   316.73 (-0.68%)
MSFT   181.57 (-1.06%)
FB   232.20 (-1.15%)
GOOGL   1,421.37 (+0.58%)
AMZN   2,421.86 (-0.62%)
NVDA   348.71 (-3.42%)
CGC   20.01 (+3.04%)
BABA   201.72 (+1.01%)
MU   45.80 (+1.91%)
GE   6.80 (+6.08%)
TSLA   818.87 (+0.24%)
AMD   53.19 (-3.59%)
T   30.82 (+3.15%)
ACB   15.61 (-2.50%)
F   5.84 (+3.36%)
GILD   73.18 (-0.22%)
DIS   120.95 (+2.48%)
NFLX   414.77 (-3.39%)
BAC   24.28 (+7.15%)
BA   144.73 (+5.24%)
Log in

LON:SLNSilence Therapeutics Share Price, Forecast & News

GBX 446
-9.00 (-1.98 %)
(As of 05/26/2020 04:00 PM ET)
Add
Compare
Today's Range
440
Now: GBX 446
468
50-Day Range
363
MA: GBX 423.28
483
52-Week Range
42
Now: GBX 446
646.50
Volume54,871 shs
Average Volume13,380 shs
Market Capitalization£369.27 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Silence Therapeutics plc focuses on the discovery, development, and delivery of novel RNA therapeutics. The company designs short interfering RNA (siRNA) molecules that trigger the RNAi pathway and mediate the degradation of specific target messenger RNAs. It is developing various candidates for the treatment of cancer, iron overload disorders, cardiovascular disease, alcohol use disorder, and other metabolic diseases. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.
Read More
Silence Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.35 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+44-20-34576900

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales£244,000.00
Cash FlowGBX 42.14 per share
Book ValueGBX 26.70 per share

Profitability

Miscellaneous

EmployeesN/A
Market Cap£369.27 million
Next Earnings DateN/A
OptionableNot Optionable

Receive SLN News and Ratings via Email

Sign-up to receive the latest news and ratings for SLN and its competitors with MarketBeat's FREE daily newsletter.

Silence Therapeutics (LON:SLN) Frequently Asked Questions

How has Silence Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Silence Therapeutics' stock was trading at GBX 470 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, SLN stock has decreased by 5.1% and is now trading at GBX 446. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Silence Therapeutics?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Silence Therapeutics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Silence Therapeutics.

How were Silence Therapeutics' earnings last quarter?

Silence Therapeutics plc (LON:SLN) posted its quarterly earnings data on Tuesday, September, 11th. The company reported ($12.40) EPS for the quarter. View Silence Therapeutics' earnings history.

What price target have analysts set for SLN?

1 brokers have issued 12-month target prices for Silence Therapeutics' shares. Their forecasts range from GBX 605 to GBX 605. On average, they expect Silence Therapeutics' stock price to reach GBX 605 in the next twelve months. This suggests a possible upside of 35.7% from the stock's current price. View analysts' price targets for Silence Therapeutics.

Has Silence Therapeutics been receiving favorable news coverage?

News coverage about SLN stock has been trending negative this week, InfoTrie reports. The research group ranks the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Silence Therapeutics earned a media sentiment score of -2.6 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 9.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the near future. View the latest news aboutSilence Therapeutics.

Who are some of Silence Therapeutics' key competitors?

What other stocks do shareholders of Silence Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Silence Therapeutics investors own include Arch Therapeutics (ARTH), QuickLogic (QUIK), Asiamet Resources (ARS), ArcBest (ARCB), American Renal Associates (ARA), Apergy (APY), ANCHIANO THERAP/S (ANCN), Aileron Therapeutics (ALRN), Alkermes (ALKS) and Alfa Financial Software (ALFA).

Who are Silence Therapeutics' key executives?

Silence Therapeutics' management team includes the following people:
  • Dr. David Horn Solomon, CEO & Director (Age 59)
  • Dr. Rob Quinn, Chief Financial Officer
  • Dr. Mark Cameron, Head of Chemistry
  • Mr. Richard Jenkins, Head of Clinical Devel.

What is Silence Therapeutics' stock symbol?

Silence Therapeutics trades on the London Stock Exchange (LON) under the ticker symbol "SLN."

How do I buy shares of Silence Therapeutics?

Shares of SLN and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Silence Therapeutics' stock price today?

One share of SLN stock can currently be purchased for approximately GBX 446.

How big of a company is Silence Therapeutics?

Silence Therapeutics has a market capitalization of £369.27 million and generates £244,000.00 in revenue each year.

What is Silence Therapeutics' official website?

The official website for Silence Therapeutics is www.silence-therapeutics.com.

How can I contact Silence Therapeutics?

Silence Therapeutics' mailing address is 72 Hammersmith Road, LONDON, W14 8TH, United Kingdom. The company can be reached via phone at +44-20-34576900.

This page was last updated on 5/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.